Iwilfin is a drug owned by Uswm Llc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 12, 2036. Details of Iwilfin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12582625 | NA |
Feb, 2036
(9 years from now) | Active |
FDA has granted several exclusivities to Iwilfin. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Iwilfin, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Iwilfin.
Exclusivity Information
Iwilfin holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Iwilfin's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 13, 2026 |
| Orphan Drug Exclusivity(ODE-462) | Dec 13, 2030 |
US patents provide insights into the exclusivity only within the United States, but
Iwilfin is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Iwilfin's family patents as well as insights into
ongoing legal events
on those patents.
Iwilfin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Iwilfin's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 12, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Iwilfin Generics:
There are no approved generic versions for Iwilfin as of now.
Alternative Brands for Iwilfin
There are several other brand drugs using the same active ingredient (Eflornithine Hydrochloride) as Iwilfin. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
|
About Iwilfin
Iwilfin is a drug owned by Uswm Llc. Iwilfin uses Eflornithine Hydrochloride as an active ingredient. Iwilfin was launched by Uswm in 2023.
Approval Date:
Iwilfin was approved by FDA for market use on 13 December, 2023.
Active Ingredient:
Iwilfin uses Eflornithine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Eflornithine Hydrochloride ingredient
Dosage:
Iwilfin is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 192MG BASE | TABLET | Prescription | ORAL |